Pioneer Pharma plans to acquire all shares of Conflux, and the two parties have signed a memorandum of understanding.

robot
Abstract generation in progress

On July 1, Hong Kong listed company Pioneer Pharmaceutical Biotechnology (00399) announced that on June 30, 2025, the company (, as the buyer ), has signed a memorandum of understanding with the seller ( Northwestern Foundation ) and Conflux regarding the potential acquisition of all equity of the target company, contingent upon the target company completing the acquisition of Conflux assets according to the agreement with the company. Conflux is a limited company registered in Hong Kong, primarily engaged in the development of blockchain technology. The target company is a limited company that will be registered in the Cayman Islands and wholly owned by the seller. The company is actively exploring new business opportunities to diversify its revenue sources and implement strategic plans to enhance performance, as well as planning to expand its business into blockchain technology and enter the digital innovation industry. Signing the memorandum of understanding indicates the company's commitment to entering the digital innovation industry through potential acquisition activities to develop this new business division. The company believes that this move will not only diversify the group's business but also bring new profit growth momentum to the group.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)